Istaroxime has previously completed two positive Phase 2 studies in SCAI Stage B cardiogenic shock; the SEISMiC C study in SCAI Stage C cardiogenic shock is another step progressing to the istaroxime ...
WARRINGTON, Pa., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage ...
Numerous knowledge gaps exist regarding the care of female patients with cardiogenic shock, often because they have been consistently underrepresented in clinical trials, according to a new consensus ...
A 2026 mini review finds that mechanical circulatory support in cardiogenic shock should be matched to ventricular and ...
More than a quarter of patients with early-stage cardiogenic shock had to be transferred to a higher level of care, progressed to a worse stage of shock, or died, according to a study in six US ...
MONTREAL – April 23, 2026 – Findings from the Can Escalation Reduce Acute Myocardial Infarction Mortality in Cardiogenic Shock (CERAMICS) registry demonstrate that early use of a small heart pump ...
WARRINGTON, Pa., May 22, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT), a biotechnology company focused on becoming a revenue-generating company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results